Aura Biosciences Prepares for Phase IIa Trial

Aura Biosciences is preparing to conduct a Phase IIa trial of its light-activated AU-011 therapy for treatment of ocular melanoma, CEO Elisabet de los Pinos, PhD, reported at the Company Showcase 3 session at OIS@AAO 2017. Two days later at the American Academy of Ophthalmology Retina Subspecialty Day, Carol Shields, MD, of Wills Eye Hospital in Philadelphia, reported interim data from the Phase Ib/II trial that showed the drug candidate was well tolerated in the first six patients treated with AU-011 at three- to six-months post-treatment. Now Aura is preparing for a dose optimization study with plans to go into Phase III in 2018/2019, Dr. de los Pinos said.